HELP:NASDAQ
Cybin Inc
12,70 USD
arrow_upward
+0,87%(+0,11) 1D
12,85 USD
arrow_upward
+1,18% (+0,15)bedtimeNakon radnog vremena
Zatvoreno: 29. ruj, 16:00:01 GMT -4 · USD
search
Svi simboli
1D
5D
1M
6M
GDD
1G
5G
MAKS
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za HELP...
Otvori
12,60 USD
Najviša
12,96 USD
Najniža
12,44 USD
Prosj. kol.
1,73 mil.
Količina
972,66 tis.
52-tjed. najviša
15,15 USD
52-tjed. najniža
3,76 USD
Beta
0,63
Dionice u optjecaju
73,06 mil.
Broj djelatnika
100
Otvori
12,60 USD
Najviša
12,96 USD
Najniža
12,44 USD
Prosj. kol.
1,73 mil.
Količina
972,66 tis.
52-tjed. najviša
15,15 USD
52-tjed. najniža
3,76 USD
Beta
0,63
Dionice u optjecaju
73,06 mil.
Broj djelatnika
100
Profil
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Cybin Inc – informacije
Glavni izvršni direktor-
Zaposlenici100
Osnovano2019
SjedišteToronto, Ontario, Kanada
Sektor-
Web-lokacijahelus.com